SG11202105949RA - Crystalline forms and salt forms of a kinase inhibitor - Google Patents
Crystalline forms and salt forms of a kinase inhibitorInfo
- Publication number
- SG11202105949RA SG11202105949RA SG11202105949RA SG11202105949RA SG11202105949RA SG 11202105949R A SG11202105949R A SG 11202105949RA SG 11202105949R A SG11202105949R A SG 11202105949RA SG 11202105949R A SG11202105949R A SG 11202105949RA SG 11202105949R A SG11202105949R A SG 11202105949RA
- Authority
- SG
- Singapore
- Prior art keywords
- forms
- kinase inhibitor
- salt
- crystalline
- crystalline forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US201962856469P | 2019-06-03 | 2019-06-03 | |
| PCT/US2019/065972 WO2020123800A1 (en) | 2018-12-13 | 2019-12-12 | Crystalline forms and salt forms of a kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105949RA true SG11202105949RA (en) | 2021-07-29 |
Family
ID=69160358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105949RA SG11202105949RA (en) | 2018-12-13 | 2019-12-12 | Crystalline forms and salt forms of a kinase inhibitor |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3894012A1 (en) |
| JP (2) | JP2022512399A (en) |
| KR (1) | KR20210102381A (en) |
| CN (1) | CN113329790A (en) |
| AU (1) | AU2019395419A1 (en) |
| BR (1) | BR112021011333A2 (en) |
| CA (1) | CA3122840A1 (en) |
| CL (1) | CL2021001537A1 (en) |
| CO (1) | CO2021007613A2 (en) |
| CR (1) | CR20210375A (en) |
| GE (1) | GEP20247596B (en) |
| IL (1) | IL283860A (en) |
| MA (1) | MA54458A (en) |
| MX (1) | MX2021006951A (en) |
| PE (1) | PE20211757A1 (en) |
| PH (1) | PH12021551356A1 (en) |
| SG (1) | SG11202105949RA (en) |
| TW (1) | TW202039440A (en) |
| WO (1) | WO2020123800A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20200358A (en) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| WO2021222673A1 (en) * | 2020-04-30 | 2021-11-04 | Exelixis, Inc. | Processes for the preparation of a kinase inhibitor |
| CN116437954A (en) | 2020-07-31 | 2023-07-14 | 埃克塞里艾克西斯公司 | Combination for the treatment of cancer |
| CA3196001A1 (en) | 2020-11-05 | 2022-05-12 | Exelixis, Inc. | Pharmaceutical compositions of a kinase inhibitor |
| CN112650176B (en) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | DCS control method for hydrochloric acid analysis start-stop process |
| TW202334090A (en) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | Compounds for the treatment of kinase-dependent disorders |
| CA3240202A1 (en) | 2021-12-22 | 2023-06-29 | Kirsten Phizackerley | Crystalline forms and salt forms of a kinase inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4638436B2 (en) * | 2003-09-26 | 2011-02-23 | エグゼリクシス， インコーポレイテッド | c-Met modulators and uses thereof |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| CN107892719B (en) | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | Human monoclonal anti-PD-L1 antibodies and methods of use |
| CN105339389B (en) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | Antibodies against programmed death-1 (PD-1) |
| CR20200358A (en) * | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
-
2019
- 2019-12-12 AU AU2019395419A patent/AU2019395419A1/en active Pending
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/en unknown
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/en active Pending
- 2019-12-12 KR KR1020217021734A patent/KR20210102381A/en unknown
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/en active Application Filing
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 CA CA3122840A patent/CA3122840A1/en active Pending
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/en unknown
- 2019-12-12 EP EP19836338.4A patent/EP3894012A1/en active Pending
- 2019-12-12 JP JP2021533537A patent/JP2022512399A/en active Pending
- 2019-12-12 CR CR20210375A patent/CR20210375A/en unknown
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/en unknown
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 MA MA054458A patent/MA54458A/en unknown
- 2019-12-13 TW TW108145868A patent/TW202039440A/en unknown
-
2021
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-09 IL IL283860A patent/IL283860A/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/en unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/en unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP2024038167A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021007613A2 (en) | 2021-06-21 |
| CL2021001537A1 (en) | 2022-02-04 |
| CA3122840A1 (en) | 2020-06-18 |
| BR112021011333A2 (en) | 2021-08-31 |
| MX2021006951A (en) | 2021-07-15 |
| EP3894012A1 (en) | 2021-10-20 |
| US20230029213A1 (en) | 2023-01-26 |
| KR20210102381A (en) | 2021-08-19 |
| JP2022512399A (en) | 2022-02-03 |
| CR20210375A (en) | 2021-08-18 |
| GEP20247596B (en) | 2024-02-26 |
| JP2024038167A (en) | 2024-03-19 |
| PE20211757A1 (en) | 2021-09-07 |
| CN113329790A (en) | 2021-08-31 |
| AU2019395419A1 (en) | 2021-07-01 |
| WO2020123800A1 (en) | 2020-06-18 |
| MA54458A (en) | 2021-10-20 |
| TW202039440A (en) | 2020-11-01 |
| IL283860A (en) | 2021-07-29 |
| PH12021551356A1 (en) | 2021-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283860A (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| IL270872A (en) | Crystalline forms of a fgfr inhibitor and processes for preparing the same | |
| SG11202010882XA (en) | Salts of an fgfr inhibitor | |
| IL288062A (en) | Solid state forms of tafamidis and salts thereof | |
| EP3619208C0 (en) | Crystalline forms of a jak inhibitor compound | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| HK1256806A1 (en) | Salts of a pim kinase inhibitor | |
| IL282552A (en) | Crystalline forms of mnk inhibitors | |
| IL290106A (en) | Crystalline form of atr inhibitor and use thereof | |
| IL267393B1 (en) | Crystalline forms of a janus kinase inhibitor | |
| IL281168A (en) | Crystalline forms of a quinazole compound and its hydrochloride salts | |
| IL274027A (en) | Crystalline salts of a b-raf kinase inhibitor | |
| SG11202106210QA (en) | Salt of syk inhibitor and crystalline form thereof | |
| IL277806A (en) | Growth inhibitor | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| IL277578A (en) | Novel salt forms of urat-1 inhibitors | |
| IL279953A (en) | Crystalline forms of a lta4h inhibitor | |
| IL272835A (en) | The salts of a compound and the crystalline forms thereof | |
| SG11202009262VA (en) | Salts of compounds and crystals thereof | |
| SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
| GB201912411D0 (en) | Crystalline forms of ivosidenib | |
| IL284222A (en) | Crystalline forms of a par4 inhibitor | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| IL305791A (en) | Salt and solid forms of a kinase inhibitor | |
| IL292206A (en) | The salts of a compound and the crystalline forms thereof |